Christoph Thomssen
A5001617286- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Estrogen and related hormone effects
- Breast Lesions and Carcinomas
- Protease and Inhibitor Mechanisms
- BRCA gene mutations in cancer
- Cancer Genomics and Diagnostics
- Global Cancer Incidence and Screening
- Cancer Immunotherapy and Biomarkers
- Economic and Financial Impacts of Cancer
- Cell Adhesion Molecules Research
- Monoclonal and Polyclonal Antibodies Research
- Lung Cancer Treatments and Mutations
- RNA modifications and cancer
- Peptidase Inhibition and Analysis
- Cancer Diagnosis and Treatment
- Ovarian cancer diagnosis and treatment
- Colorectal Cancer Treatments and Studies
- PARP inhibition in cancer therapy
- Cancer-related Molecular Pathways
- Biosimilars and Bioanalytical Methods
- Cervical Cancer and HPV Research
- Cancer, Lipids, and Metabolism
Martin Luther University Halle-Wittenberg
2015-2024
University Hospital in Halle
2014-2024
Luther University
2008-2023
Klinik und Poliklinik für Urologie
2006-2023
University of Hildesheim
2017-2022
University Medical Centre Mannheim
2021
Klinik und Poliklinik für Neurologie
2003-2021
Edinburgh Cancer Research
2021
Klinik für Frauenheilkunde
2001-2020
University Medical Center Hamburg-Eppendorf
2006-2019
Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in advanced breast cancer that overexpresses HER2. We investigated its efficacy and safety after excision of early-stage completion chemotherapy.
Advanced Breast Cancer (ABC) comprises both locally advanced (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains an incurable disease with a median overall survival of ∼2–3 years 5-year only ∼25% [2–4]. Some more recent series seem to indicate improvement in [5, 6].
Advanced Breast Cancer (ABC) comprises both locally advanced breast cancer (LABC) and metastatic (MBC) [1.Cardoso F. Costa A. Norton L. ESO-ESMO 2nd International Consensus Guidelines for (ABC2). Simultaneous publication in.Breast. 2014; 23: 489-502Abstract Full Text PDF PubMed Scopus (252) Google Scholar]. Although treatable, MBC remains virtually an incurable disease with a median overall survival (OS) of ∼3 years 5-year only ∼25% [2.Cardoso Spence D. Mertz S. et al.Global analysis...
Background: Urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) play essential roles in tumor invasion metastasis. High levels of both uPA PAI-1 are associated with poor prognosis breast cancer patients. To confirm the prognostic value primary cancer, we reanalyzed individual patient data provided by members European Organization for Research Treatment Cancer–Receptor Biomarker Group (EORTC-RBG). Methods: The study included 18 datasets involving 8377 During follow-up (median...
PURPOSE Trastuzumab, a humanized antibody against the human epidermal growth factor receptor type 2 (HER2), has shown high efficacy in breast cancer. We prospectively investigated its given simultaneously with anthracycline-taxane-based neoadjuvant chemotherapy. PATIENTS AND METHODS Patients operable or locally advanced, HER2-positive tumors were treated preoperatively four cycles of epirubicin/cyclophosphamide followed by docetaxel without capecitabine (EC-T[X]) and trastuzumab 6 mg/kg...
Advanced breast cancer (ABC) is a treatable but still generally incurable disease. The goals of care are to optimize both length and quality life. Due continuous research, several advances have been made, particularly for the human epidermal growth factor receptor 2 (HER-2)-positive luminal-like subtypes. Notwithstanding these advances, median overall survival patients with ABC only 2–3 years, although range wide [1–5], may be longer treated in specialized institutions [6].
Background: Most patients with lymph node-negative breast cancer are cured by locoregional treatment; however, about 30% relapse. Because traditional histomorphologic and clinical factors fail to identify the high-risk who may benefit from adjuvant chemotherapy, other prognostic needed. In a unicenter study, we have found that levels of urokinase-type plasminogen activator (uPA) inhibitor type 1 (PAI-1) in primary tumor predictive disease recurrence. Thus, designed Chemo N0 prospective...
Extravasation and intravasation of solid malignant tumors is controlled by attachment tumor cells to components the basement membrane extracellular matrix, local proteolysis cell migration. Strong clinical experimental evidence has accumulated that tumor-associated serine protease plasmin, its activator uPA (urokinase-type plasminogen activator), receptor uPA-R (CD87), inhibitors PAI-1 PAI-2 are linked cancer invasion metastasis. In cancer, increase uPA, uPA-R, and/or associated with...
We aimed to determine the prognosis of patients with breast cancer diagnosed during pregnancy (BCP).In this cohort study, a multicentric registry BCP (from Cancer in Pregnancy, Leuven, Belgium, and GBG 29/BIG 02-03) compiled pro- retrospectively between 2003 2011 was compared who did not have associated pregnancies, using an age limit 45 years. Patients diagnosis postpartum were excluded. The main analysis performed Cox proportional hazards regression disease-free survival (DFS) overall (OS)...
Advanced Breast Cancer (ABC) is a treatable but still generally incurable disease. The goals of care are to optimize both length and quality life. Due continuous research, several advances have been made, particularly for the HER-2-positive Luminal-like subtypes. Notwithstanding these advances, median overall survival patients with ABC only 2–3 years, although range wide [1–5], may be longer treated in specialized institutions [6]. Implementation current knowledge highly variable among...
The 1st international Consensus Conference for Advanced Breast Cancer (ABC 1) took place on November 2011, in Lisbon.Consensus guidelines the management of this disease were developed.This manuscript summarizes these consensus guidelines.
APHINITY, at 45 months median follow-up, showed that pertuzumab added to adjuvant trastuzumab and chemotherapy significantly improved invasive disease-free survival (IDFS) (hazard ratio 0.81 [95% CI, 0.66 1.00], P = .045) for patients with early human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC), specifically those node-positive or hormone (HR)-negative disease. We now report the preplanned second interim overall (OS) descriptive updated IDFS analysis 74...
Advanced Breast Cancer (ABC) comprises both locally advanced (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, it is remains an incurable disease with a median overall survival of ∼2–3 years 5-year only ∼25% [2–4]. Some more recent series seem to indicate improvement in [5,6].
The 2011 St. Gallen Consensus Conference on early breast cancer provided mostly evidence-based treatment recommendations with a broad spectrum of acceptable clinical practice for global care. This report summarizes the results international panel voting procedures regard to locoregional and endocrine treatment, chemotherapy, targeted therapy as well adjuvant bisphosphonate use.
Breast cancer during pregnancy (BCP), although rare, is becoming more common and treatment should be as similar possible to that for nonpregnant young patients with breast cancer. A group of specialists convened review current guidelines provide guidance on how recent advances in diagnosis can adapted pregnant patients. The majority BCP will considered the pregnancy. Premature delivery avoided whenever possible. Most treatments, including sentinel lymph node biopsy, systemic therapy taxanes,...
This manuscript describes the Advanced Breast Cancer (ABC) international consensus guidelines updated at last two ABC conferences (ABC 6 in 2021, virtual, and 7 2023, Lisbon, Portugal), organized by Global Alliance. It provides main recommendations on how to best manage patients with advanced breast cancer (inoperable locally or metastatic), of all subtypes, as well palliative supportive care. These are based available evidence expert opinion when a higher level is lacking. Each guideline...